[go: up one dir, main page]

WO2007134142A3 - Methods and compositions for identifying and using p21-regulated proteins - Google Patents

Methods and compositions for identifying and using p21-regulated proteins Download PDF

Info

Publication number
WO2007134142A3
WO2007134142A3 PCT/US2007/068619 US2007068619W WO2007134142A3 WO 2007134142 A3 WO2007134142 A3 WO 2007134142A3 US 2007068619 W US2007068619 W US 2007068619W WO 2007134142 A3 WO2007134142 A3 WO 2007134142A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
identifying
regulated proteins
compositions
proteins
Prior art date
Application number
PCT/US2007/068619
Other languages
French (fr)
Other versions
WO2007134142A2 (en
Inventor
William Gallagher
Darran O'connor
Caroline Currid
Igor Roninson
Original Assignee
Univ Dublin
William Gallagher
Darran O'connor
Caroline Currid
Igor Roninson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dublin, William Gallagher, Darran O'connor, Caroline Currid, Igor Roninson filed Critical Univ Dublin
Publication of WO2007134142A2 publication Critical patent/WO2007134142A2/en
Publication of WO2007134142A3 publication Critical patent/WO2007134142A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

This disclosure identifies p21-regulated proteins that may be used to induce anti- apoptotic and/or mitogenic cellular effects, both paracrine and within the p21-expressing cell itself. Three proteins released from HT- 1080 human fibrosarcoma cells displaying inducible p21 expression were identified; β-2-microglobulin, cystatin C, and pro-platelet basic protein. The disclosure also provides therapeutic compositions, methods for using, and methods for identifying p21-regulated proteins.
PCT/US2007/068619 2006-05-11 2007-05-10 Methods and compositions for identifying and using p21-regulated proteins WO2007134142A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79947906P 2006-05-11 2006-05-11
US60/799,479 2006-05-11

Publications (2)

Publication Number Publication Date
WO2007134142A2 WO2007134142A2 (en) 2007-11-22
WO2007134142A3 true WO2007134142A3 (en) 2008-08-21

Family

ID=38694688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068619 WO2007134142A2 (en) 2006-05-11 2007-05-10 Methods and compositions for identifying and using p21-regulated proteins

Country Status (1)

Country Link
WO (1) WO2007134142A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427916A (en) * 1988-05-09 1995-06-27 Temple University Of The Commonwealth System Of Higher Education Method for predicting the effectiveness of antineoplastic therapy in individual patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427916A (en) * 1988-05-09 1995-06-27 Temple University Of The Commonwealth System Of Higher Education Method for predicting the effectiveness of antineoplastic therapy in individual patients

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GLEICH: "Gene therapy for head and neck cancer", LARYNGOSCOPE, vol. 110, 2000, pages 708 - 726 *
GORDON ET AL.: "beta2-microglobulin induces caspase-dependent apoptosis in the CCRF-HSB-2 human leukemic cell line independently of the caspase-3, -8, and -9 pathways but through increased reactive oxygen species", INT. J. CANCER, vol. 103, 2003, pages 316 - 327 *
GRUNDTVIG ET AL.: "Beta-2-microglobulin excretion: an indicator of long term nephrotoxicity during cis-platinum treatment", CANCER CHEMOTHER. PHARMACOL., vol. 14, 1985, pages 247 - 249 *
MATIN ET AL.: "Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells", STEM CELLS, vol. 22, 2004, pages 659 - 668, XP008035005 *
MORI ET AL.: "Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: caspase-3 and nuclear factor-kappaB", CANCER RESEARCH, vol. 61, June 2001 (2001-06-01), pages 4414 - 4417 *
OGRETMEN ET AL.: "Molecular mechanisms of loss of beta2-microglobulin expression of drug-resistant breast cancer sublines and its involvement in drug resistance", BIOCHEMISTRY, vol. 37, 1998, pages 11679 - 11691, XP055030985, DOI: doi:10.1021/bi980573c *
WU ET AL.: "beta2-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein", ONCOGENE, vol. 20, 2001, pages 7006 - 7020 *

Also Published As

Publication number Publication date
WO2007134142A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
FR22C1052I2 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN THE TREATMENT OF TUMORS, TRANSPLANTATION AND AUTOIMMUNE DISEASES
WO2008133722A3 (en) Anti human sclerostin antibodies
HUS1800021I1 (en) Human anti-il-23 antibodies, compositions, methods and uses
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
TW200806317A (en) Methods for reducing protein aggregation
WO2007044534A3 (en) Vegf analogs and methods of use
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
DE60135498D1 (en) Production of Whole Antibodies in Prokaryotic Cells
EP3252079B8 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2010102251A3 (en) Il-17 binding proteins
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2007117564A3 (en) Clay-binding peptides and methods of use
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
WO2007111661A3 (en) Human antibodies specific for gastrin materials and methods
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
WO2011087795A3 (en) Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
WO2004094476A3 (en) Compositions and methods relating to stop-1
SG158133A1 (en) Method for reversing multiple resistance in animal cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07762075

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07762075

Country of ref document: EP

Kind code of ref document: A2